A5364: A Phase I Open-Label Study of the | Clinical Research Studies Listing

Recruiting

99 years or below

All

1 Location

Brief description of study

The main purpose of this study is to see if it is safe to give people 10-1074-LS and 3BNC117-LS and to see if these study drugs cause any side effects. We also want to see how the study drugs affect the level of HIV in the blood when you are not taking your regular drugs to control HIV for an extended period of time. This extended period of time when you are not taking your regular drugs to control HIV is referred to as analytical treatment interruption (also called ATI).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 11 Jan 2023. Study ID: 851543

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A5364: A Phase I Open-Label Study of the Safety and Ability of Broadly Neutralizing Antibodies 3BNC117-LS and 10-1074-LS in Combination to Durably Prevent Viral Relapse During a Monitored Analytical Treatment Interruption

Brief description of study

Eligibility of study

Find a site

Interested in the study